Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2019 02/15/2019 02/19/2019 02/20/2019 02/21/2019 Date
414.97(c) 423.97(c) 420.6(c) 422.51(c) 418.62(c) Last
349 604 700 044 397 795 411 138 406 583 Volume
+0.70% +2.17% -0.79% +0.45% -0.92% Change
More quotes
Financials (USD)
Sales 2019 7 357 M
EBIT 2019 2 960 M
Net income 2019 2 233 M
Finance 2019 6 456 M
Yield 2019 -
Sales 2020 7 970 M
EBIT 2020 3 201 M
Net income 2020 2 412 M
Finance 2020 9 046 M
Yield 2020 -
P/E ratio 2019 21,75
P/E ratio 2020 20,13
EV / Sales2019 5,23x
EV / Sales2020 4,50x
Capitalization 44 945 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (63.3%); - supply of collaborative services (30.9%): working with Bayer... 
Sector
Biotechnology & Medical Research
Calendar
03/11 | 10:20amPresentation
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
02/18REGENERON PHARMACEUTICALS : U.s. and eu patent office decisions invalidate amgen..
AQ
02/15REGENERON PHARMACEUTICALS : U.S. and EU Patent Office Decisions Invalidate Amgen..
PR
02/14REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
02/12REGENERON PHARMACEUTICALS : and Sanofi Offer Praluent at a New Reduced U.S. List..
AQ
02/11REGENERON PHARMACEUTICALS : One-Year Results from Positive Phase 3 EYLEA Trial i..
AQ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/11REGENERON PHARMACEUTICALS : and Sanofi Offer Praluent® (alirocumab) at a New Red..
PR
02/09REGENERON PHARMACEUTICALS : One-Year Results from Positive Phase 3 EYLEA Trial i..
PR
02/07REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
RE
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Updat..
DJ
02/04GILEAD SCIENCES : Raises Dividend by 6 Cents a Share
DJ
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 427 $
Spread / Average Target 2,0%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS13.51%44 945
GILEAD SCIENCES6.73%86 647
VERTEX PHARMACEUTICALS13.49%48 023
GENMAB-5.57%9 415
SAREPTA THERAPEUTICS INC25.12%9 393
BLUEBIRD BIO INC38.14%7 298